Risperidone in the treatment of acute schizophrenia

Journal of Clinical Psychopharmacology

Volumn 24, Issue 3, 2004, Pages 335-338

  Raedler, Thomas J ^a   Schreiner, Andreas ^b   Naber, Dieter ^a   Wiedemann, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b Dept of Med and Scientific Affairs ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; RISPERIDONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; SYMPTOM;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA;

EID: 2442701654     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000126660.50788.ef     Document Type: Article

References (8)

1. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
2. Leucht S, Barnes TRE, Kissling W, et al. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003;160:1209-1222.
3. Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346:16-22.
4. Hunter RH, Joy CB, Kennedy E, et al. Risperidone versus typical antipsychotic medication for schizophrenia [Cochrane review]. Cochrane Database Syst Rev. 2003;2:CD000440.
5. Kay SR, Opler LA, Fiszbein A. Positive and Negative Symptoms in Schizophrenia: Assessment and Research. New York: Bruner Mazel; 1991.
6. Guy W. ECDEU Assessment Manual for Psychopharmacology. 338. Washington, DC: US Department of Health and Welfare. 1976:534-537.
7. Currier GW, Simpson GM. Risperidone liquid concentrate and oral lorazepam versus intramuscular haloperidol and intramuscular lorazepam for treatment of psychotic agitation. J Clin Psychiatry. 2001;62:153-157.
8. McAllister-Williams RH, Ferrier IN. Rapid tranquilisation: time for reappraisal of options for parenteral therapy. Br J Psychiatry. 2001;179:485-489.